CALGARY, Alberta – (August 31, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) highlights recent research indicating a link between non-alcoholic steatohepatitis (NASH) and Alzheimer’s Disease (AD), two programs its lead asset, MB-204 are targeting.
A five-year longitudinal study in Sweden tracked subjects with and without NASH over the age of 65, and those with NASH had a 38% higher risk of developing dementia (1). With up to 25% of the population suffering with NASH, this could worsen the already an alarming number of elderly patients with dementia which is estimated at more than 7 million diagnosed patients in the US alone (2).
“The link between NASH and AD is of concern, especially with an aging population,” said Dr. Mark Williams, Chief Science Officer of Marvel. “Caffeine consumption appears to be protective in both diseases, and one of the key targets of caffeine is the adenosine A2a receptor. Our lead asset, MB-204 also targets the adenosine A2a receptor and has been shown in preclinical studies to improve NASH and depressive symptoms, the latter of which is common in Alzheimer’s Disease patients as well.”
“Currently there are no approved treatments for NASH, and very few effective treatment options for AD patients,” said Rod Matheson, CEO of Marvel. “We are looking forward to advancing MB-204 to the clinic later this year with the hopes of being able to address both of these underserved conditions”.
(1). Neurology (2022) 99:e574-e582
Investor Relations: Marvel Biosciences Corp.
Virtus Advisory Group Roderick (Rod) Matheson, Chief Executive Officer or
Tel: 416-644-5081 Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.